mg BID

Related by string. * MGS . MGD . Mg . mgd . MGs . mgs . MG . mG . MGd . Mgd : Yard Freestyle =-#.# mg dL . mg kg dose . mg tablets . mg mL . mg ml . kilogram mg kg . mg QD . mg kg . mg capsules . MG Rover / BIS . Bid . Bier . bis . Bi . Bis . bier . BiS . bid . bi : Normal Course Issuer Bid . bi racial . BI BB SO . bi weekly . bi coastal . bid fond farewell . Permitted Bid provisions . hostile takeover bid . bi partisan . BID * mg BID dose *

Related by context. All words. (Click for frequent words.) 80 mg QD 75 mcg BID 75 mcg kg 74 mg dose 74 mg TID 74 lopinavir r 74 lopinavir r arm 74 peginterferon alfa 2a 73 4mg/kg 73 8mg/kg 73 #mg QD [002] 72 #mg/m# [001] 72 #mg BID [003] 72 plus methotrexate 72 oxycodone CR 72 mcg QD 72 mg qd 72 FOLFOX 72 ACR# response 71 ACTEMRA TM 71 mcg albinterferon alfa 2b 71 CIMZIA TM 71 mg/m2 71 achieved ACR# 71 #mg/day [001] 71 mg kg dose 70 μg dose 70 adalimumab 70 #mg BID [001] 70 mg/m2 dose 70 LEXIVA r 70 TMC# r 70 HBeAg seroconversion 70 alfa 2a 69 FOLFIRI 69 tapentadol ER 69 PREZISTA r 69 ritonavir boosted 69 mg ustekinumab 69 Peg IFN 69 active comparator 69 mcg dose 69 lacosamide 69 q#h 69 #mg/m# [002] 69 tipranavir r 69 mg/m2/day 69 discontinuations due 69 peginterferon alfa 2b 69 events AEs 69 daunorubicin 69 placebo dexamethasone 69 mcg Albuferon 69 adjunctive placebo 69 APTIVUS r 68 achieved PASI 68 3mg/kg 68 mg d 68 ascending doses 68 chlorambucil 68 REYATAZ r arm 68 plus prednisone 68 plus dexamethasone 68 evaluable patients 68 carboplatin paclitaxel 68 certolizumab 68 ascending dose 68 abacavir lamivudine 68 zonisamide SR 68 ug kg 68 evaluable 68 virologic failure 68 desvenlafaxine succinate 68 ATACAND 68 LEXIVA 68 Flu Cy 68 virologic response 68 FOLFOX4 68 posaconazole 68 ribavirin RBV 68 CANCIDAS 67 mg m² 67 tiotropium 67 Psoriasis Area 67 #mg/day [002] 67 plus MTX 67 mcg doses 67 RLAI 67 atazanavir ritonavir 67 VELCADE melphalan 67 #.#g/day 67 monotherapy 67 MCyR 67 pegylated interferon alfa 2a 67 placebo 67 weekly subcutaneous injections 67 budesonide pMDI 67 administered subcutaneously 67 mg q#h 67 interferon alfa 2a 67 plus gemcitabine 67 #mg QD [001] 67 dapagliflozin plus 67 mg RDEA# 67 piperacillin tazobactam 67 quetiapine 67 interferon alfa 2b 67 insulin detemir 67 evaluable subjects 67 BARACLUDE ® 67 mCi kg 67 randomized #:# 67 pegylated interferon alfa 2b 67 saline placebo 67 peg IFN 67 Pegasys ® 67 comparator arm 67 mg doses 67 salmeterol fluticasone 67 mycophenolate mofetil 67 efavirenz EFV 66 mg subcutaneously 66 CCyR 66 FOLPI 66 doxorubicin cyclophosphamide 66 relapsed MM 66 mg kg 66 rapid virologic response 66 ritonavir boosted atazanavir 66 mg tid 66 dosing cohorts 66 #mg/kg [002] 66 tamsulosin 66 5-FU/LV 66 tirofiban 66 plus OBT 66 LANTUS R 66 ISENTRESS 66 REYATAZ r 66 LPV r 66 #μg [002] 66 primary hypercholesterolemia 66 dacarbazine 66 dose cohorts 66 baseline HbA1c 66 timepoints 66 μg kg 66 ALVESCO 66 receiving golimumab 66 severe neutropenia 66 adefovir 66 DOXIL 66 sUA 66 PREZISTA ritonavir 66 mg Lucentis 66 vandetanib 66 mg eq 66 low dose cytarabine 66 adefovir treated 66 stage IIIB 66 Engerix B 66 Q2W 66 tolvaptan 66 hypokalemia 66 adjunctive ABILIFY 66 PASI scores 66 CR nPR 66 #ug [001] 66 alpha 2a 66 oral olanzapine 66 QTcF 66 CR CRu 66 melphalan prednisone 66 dose regimens 66 candesartan cilexetil 66 leukopenia 66 Fludara 66 Pegasys plus Copegus 66 bosentan 66 glatiramer acetate 66 q8h 66 #mg dose [003] 65 fluticasone salmeterol 65 #mg dose [001] 65 HBeAg positive 65 receiving INTRON 65 dose cytarabine 65 patients evaluable 65 log# copies mL 65 dose cohort 65 fosamprenavir 65 mg BID dose 65 vicriviroc 65 octreotide LAR 65 mcg 65 lumbar spine BMD 65 mg/# h 65 certolizumab pegol 65 hypomagnesemia 65 moderate renal impairment 65 n = 65 log# IU mL 65 amoxicillin clavulanate 65 #.#mg/kg [002] 65 benazepril 65 PegIFN RBV 65 MADRS score 65 CIMZIA TM certolizumab pegol 65 tenofovir emtricitabine 65 mg simvastatin 65 SVR# 65 mitoxantrone plus 65 quetiapine XR 65 etanercept 65 mitoxantrone 65 febrile neutropenia 65 tolterodine ER 65 events SAEs 65 AEGR 65 docetaxel chemotherapy 65 sustained virologic response 65 hour bronchodilation 65 cytogenetic response 65 postmenopausal osteoporotic women 65 lispro 65 methotrexate MTX 65 #.#mg/dL 65 ABC/3TC 65 ULORIC 65 PEGINTRON TM 65 dexamethasone Decadron 65 telaprevir dosed 65 pramipexole 65 ALT flares 65 spontaneous bowel movements 65 OADs 65 azacitidine 65 teriflunomide 64 Primary endpoints 64 lamivudine refractory patients 64 Lantus ® 64 DLTs 64 #mg BID [002] 64 receiving VICTRELIS 64 plus ribavirin 64 mucosal healing 64 mg dosed twice 64 PEGASYS ® 64 Pegasys peginterferon alfa 2a 64 unresectable HCC 64 pomalidomide 64 ARCOXIA 64 Taxotere R 64 aminotransferase elevations greater 64 infliximab monotherapy 64 plus prednisone prednisolone 64 #mg q8h 64 undetectable HCV RNA 64 achieved statistical significance 64 oral allopurinol 64 dosing cohort 64 mg Proellex 64 irbesartan 64 solifenacin 64 PREZISTA r arm 64 oral rivaroxaban 64 infliximab 64 timepoint 64 PROMACTA 64 relapsed refractory multiple myeloma 64 COPEGUS 64 HBeAg negative patients 64 ibandronate 64 TEAEs 64 FOLFOX6 64 thromboembolic events 64 blinded randomized placebo controlled 64 NPH insulin 64 receiving ISENTRESS 64 oral antidiabetic medication 64 partial remissions 64 bupropion SR 64 headache nasopharyngitis 64 Acetate Rectal Suppositories 64 nadolol 64 mg/m2 IV 64 steroid dexamethasone 64 REVLIMID ® 64 placebo controlled clinical trials 64 flutamide 64 Navelbine 64 Omacetaxine mepesuccinate 64 PEG Interferon alfa 64 zolmitriptan 64 #mg dose [002] 64 rizatriptan 64 pegylated interferon alpha 64 divalproex sodium 64 definite stent thrombosis 64 nab paclitaxel 64 HCV RESPOND 2 64 lamivudine 64 Lupuzor ™ 64 CHOP chemotherapy 64 treatment emergent adverse 64 plus COPEGUS 64 metformin sulfonylurea 64 dosage regimens 64 PEG IFN 64 apremilast 64 mg/# mg [001] 64 FluCAM 64 tocilizumab 64 virological failure 64 ribavirin therapy 64 ARIXTRA 64 mg administered orally 64 unfractionated heparin UFH 64 maximal tolerated 64 NATRECOR R 64 fluconazole 64 abatacept 64 microgram kg 64 median PFS 64 neutropenia dehydration dyspnea 64 QD dosing 64 rosuvastatin #mg 64 peginterferon alfa 2a #KD 64 mcg linaclotide 64 hypophosphatemia 64 #mg doses [002] 64 Peginterferon Alfa 2a 63 infusional 5-FU/LV 63 daily Infergen 63 interferon alfa 63 ACR# responses 63 cisplatin gemcitabine 63 levetiracetam 63 TORISEL 63 cyclophosphamide doxorubicin vincristine 63 placebo p = 63 annualized relapse 63 mg/# hr 63 bendamustine 63 mg q8h 63 peginterferon alpha 2a 63 REMICADE monotherapy 63 BENICAR HCT 63 IFN α 63 statin monotherapy 63 elotuzumab 63 mapatumumab 63 protease inhibitor PI 63 Eloxatin R 63 Median PFS 63 PEGylated interferon beta 1a 63 Peginterferon 63 TMC# [001] 63 temsirolimus 63 continuous intravenous infusion 63 undetectable HBV DNA 63 biphasic insulin aspart 63 oral vancomycin 63 bleeding pallor 63 CIMZIA ™ 63 FOLFOX4 alone 63 evaluating tivozanib 63 severe exacerbations 63 valsartan 63 mcg kg REBETOL 63 baseline A1C 63 RAPTIVA 63 galiximab 63 JANUVIA 63 Aptivus ® 63 QTc 63 prucalopride 63 diuretic chlorthalidone 63 alanine aminotransferase 63 mg m 63 3TC lamivudine Epivir 63 Amrubicin 63 albinterferon alfa 2b 63 mg 63 hematologic toxicity 63 systemic corticosteroid 63 fatigue asthenia 63 methotrexate monotherapy 63 Betaferon ® 63 gemcitabine carboplatin 63 nasopharyngitis 63 fluticasone 63 PegIFN 63 estramustine 63 degarelix 63 μmol L 63 Taxotere ® 63 liposome injection 63 IIIa inhibitor 63 REMICADE ® 63 DAPT 63 Folfox 63 kBq kg 63 clodronate 63 5 FU leucovorin 63 cells uL 63 dose dexamethasone 63 endoscopic remission 63 hydroxymethyl coenzyme 63 Betaferon R 63 63 EURIDIS 63 peg interferon 63 FOLPI regimen 63 inhalations twice 63 triamcinolone 63 Capecitabine 63 HAM D# scores 63 azathioprine 63 ug dose 63 DMARD 63 Apidra ® 63 STELARA 63 COMBIVIR 63 non splenectomized 63 telaprevir dosing 63 CRESTOR #mg 63 PREZISTA rtv 63 IFN alfa 63 venlafaxine ER 63 peginterferon alfa 63 subcutaneous dose 63 LVEF 63 doripenem 63 Doxil ® 63 mg/m2 administered 63 HbA1c levels 63 PROCTOCORT ® Suppository Hydrocortisone 62 oral FTY# 62 oral diclofenac 62 fluorouracil 62 sustained virological response 62 pruritus itching 62 aspartate aminotransferase 62 virologic breakthrough 62 stage IIIb IV 62 serum urate 62 lopinavir ritonavir 62 Traficet EN 62 darunavir ritonavir 62 pegylated liposomal doxorubicin 62 fluorouracil leucovorin 62 CsA 62 mg orally 62 diabetic neuropathic pain 62 atazanavir sulfate 62 PEGylated anti 62 subcutaneous enoxaparin 62 IV bolus 62 R# #mg BID 62 experienced virologic failure 62 Pharmacokinetic parameters 62 Free Survival PFS 62 Scale EDSS score 62 #μg [001] 62 Expanded Disability Status 62 decitabine 62 anemia hemoglobin 62 mRCC 62 amprenavir 62 dexamethasone 62 alanine aminotransferase ALT 62 cytarabine daunorubicin 62 prednisone prednisolone 62 raltegravir 62 GSK# [001] 62 RRMS patients 62 Oral Fingolimod 62 -#.# log# 62 Tarceva TM 62 intermittent dosing 62 binary restenosis 62 biochemical relapse 62 transaminase elevations 62 dosing intervals 62 EDSS scores 62 TO AVOID PREGNANCY WHILE 62 humanized interleukin 6 62 REBETOL 62 acneform rash 62 Secondary endpoints 62 pegylated interferon 62 phonophobia 62 tolerability 62 MoxDuo TM IR 62 severe renal impairment 62 Pegylated Liposomal Doxorubicin 62 dasatinib Sprycel ® 62 5mg/kg 62 Elitek 62 â ‰ ¥ 62 sorafenib Nexavar 62 Tolerability 62 pooled comparator 62 mCi m 2 62 CLARITY study 62 atazanavir 62 laboratory abnormalities 62 LEVAQUIN ® 62 angiotensin converting enzyme inhibitor 62 tenofovir disoproxil fumarate 62 concomitant medications 62 SEROQUEL XR 62 Copegus ribavirin 62 sitagliptin 62 rFVIIa 62 AZT zidovudine Retrovir 62 dacarbazine DTIC 62 SCH # 62 dose colchicine 62 bronchodilation 62 Cmax 62 lamivudine monotherapy 62 mcg mL 62 APTIVUS 62 AIR CF1 62 Index CDAI 62 ACTEMRA 62 fasting plasma glucose FPG 62 ertapenem 62 β blockers 62 iniparib 62 tipranavir 62 azilsartan medoxomil 62 HCV SPRINT 62 valopicitabine 62 baminercept 62 CAELYX 62 gout flares 62 mitomycin 62 VIRAMUNE XR 62 ZOLINZA 62 aspartate aminotransferase AST 62 TDF FTC 62 oxycodone IR 62 TMC# C# 62 tapentadol IR 62 Lamictal XR 62 dose escalation phase 62 plasma uric acid 62 nucleoside naive 62 idarubicin 62 urinary N telopeptide 62 placebo intravenously 62 PegIntron 62 FROVA 62 INVEGA ® 62 ceftazidime 62 RECIST criteria 62 peripheral sensory neuropathy 62 HGS ETR2 62 randomized #:#:# 62 visilizumab 62 PRADAXA #mg 62 forodesine 62 nicardipine 62 log# 62 Adverse events 62 Double Blind Randomized 62 Lucentis monotherapy 62 fluvastatin 62 FEMALES SHOULD BE ADVISED 62 TAXOTERE R 62 cisplatin vinorelbine 62 dyskinesia PD LID 62 paclitaxel carboplatin 62 BENICAR 62 treatment naïve genotype 62 DAS# remission 62 olanzapine risperidone 62 #.#/#.# mmHg [001] 62 mg dosed 62 pyrazinamide 62 primary generalized tonic 62 hypercalcemia 62 sunitinib malate 62 antiretroviral naive 62 generalized edema 62 beta2 agonist 62 TYGACIL 62 placebo p 62 genotypic resistance 62 venlafaxine XR 62 p = NS 61 x ULN 61 microg 61 naïve HCV 61 q#d 61 safinamide 61 oral levofloxacin 61 Xeloda ® 61 darunavir r 61 NATRECOR ® 61 Lubiprostone 61 eplerenone 61 XIENCE V PROMUS Stent 61 TYKERB 61 gemcitabine cisplatin 61 valsartan amlodipine 61 ara C 61 rFSH 61 REYATAZ R 61 multicenter Phase III 61 glimepiride 61 imipenem 61 lumbar spine bone 61 FluCAM arm 61 Pharmacokinetics PK 61 REVLIMID R 61 CIMZIA R 61 inhaled fluticasone 61 refractory NSCLC 61 dalteparin 61 cinacalcet 61 enfuvirtide 61 interferon gamma 1b 61 Paraplatin ® 61 RoACTEMRA 61 copies mL 61 ZYVOX 61 achieving PASI 61 treatment naive genotype 61 VIIBRYD 61 plasma HCV RNA 61 Tiotropium 61 Adalimumab 61 intravenous bolus 61 peginterferon alfa 2a Pegasys 61 SELZENTRY 61 CRx 61 ALT normalization 61 receiving prophylactic anticoagulation 61 mesalamine granules 61 nitazoxanide 61 seropositive patients 61 mL/min/#.# m2 61 transaminases 61 incidence ≥ 61 sulfasalazine 61 Pegasys R 61 pyrexia mucositis sepsis febrile 61 blood Phe 61 clinically meaningful improvements 61 bortezomib Velcade R 61 inactive placebo 61 seroprotection 61 zidovudine lamivudine 61 pharmacokinetics PK 61 intravenous dosing 61 randomized 61 oral prednisone 61 partial onset seizures 61 placebo fluoxetine 61 sorafenib tablets 61 maximally tolerated dose 61 ORENCIA 61 adriamycin 61 Lantus R 61 INCB# [001] 61 heavily pretreated patients 61 hyperphenylalaninemia HPA due 61 ziprasidone 61 Telithromycin 61 AVODART 61 dosed orally 61 placebo controlled 61 lamotrigine 61 #:# randomization 61 ng dL 61 PRECiSE 61 cabazitaxel 61 μg 61 FOLFOX6 chemotherapy regimen 61 ONGLYZA 61 INFERGEN 61 milligram doses 61 iniparib BSI 61 recurrent genital herpes 61 HBeAg positive patients 61 Raptiva r 61 fluoxetine paroxetine 61 urate lowering therapy 61 FFNS 61 demonstrated statistically significant 61 potent CYP#A# inhibitors 61 log# reduction 61 esomeprazole 61 clinically meaningful improvement 61 FAMPYRA 61 bortezomib 61 lymphopenia 61 5FU 61 glargine 61 morphometric vertebral fractures 61 SPRYCEL ® 61 Montgomery Asberg Depression 61 intravitreal injection 61 splenectomized patients 61 dose limiting toxicities 61 subcutaneously administered 61 BEACOPP 61 multicenter randomized placebo controlled 61 Relapsing Multiple Sclerosis 61 Scale EDSS 61 PEG Intron 61 RECIST Response Evaluation Criteria 61 Zometa hazard 61 ORENCIA ® 61 limiting toxicity 61 telbivudine 61 rosuvastatin 61 bortezomib refractory 61 R ribavirin USP 61 lenalidomide dexamethasone 61 doxazosin 61 abiraterone acetate 61 low dose ritonavir 61 Monotherapy 61 Solid Tumors criteria 61 Durezol 61 dasatinib 61 abdominal pain abdominal discomfort 61 refractory AML 61 patients receiving ERBITUX 61 pioglitazone 61 #/#.# mcg 61 -#.# mg dL [002] 61 pegaptanib 61 AGILECT R 61 biologic DMARD 61 placebo PBO 61 ramipril 61 placebo controlled Phase 61 fluticasone propionate 61 CIMZIA 61 tanespimycin 61 histologically confirmed 61 Crohn Disease Activity 61 BRIM2 61 LIALDA 61 heavily pretreated 61 mg/# mg twice 61 tiotropium bromide 61 GnRH agonist 61 venlafaxine 61 unfractionated heparin 61 alpha 2b 61 dizziness nausea diarrhea 61 angiotensin receptor blocker ARB 61 insulin glargine 61 colesevelam HCl 61 ciclesonide 61 free survival PFS 61 NRTIs 61 serum potassium 61 KAPIDEX 61 doxorubicin docetaxel 61 virologic suppression 61 NRTI 61 myelosuppression 61 nadroparin 61 mg kg BID 61 Dasatinib 61 CTA# Injection 61 Pemetrexed 61 complete cytogenetic 61 IR prednisone 61 nevirapine Viramune 61 huN# DM1 61 MULTAQ 61 FUSILEV enhances 61 placebo controlled trials 61 acute bipolar mania 61 aspirin clopidogrel 61 beclomethasone dipropionate 61 vinorelbine 61 ELOXATIN 60 prior chemotherapy regimens 60 Alkeran 60 boosted protease inhibitor 60 timolol 60 standard chemotherapy regimen 60 Hycamtin ® 60 highly emetogenic 60 subcutaneous doses 60 ARB telmisartan 60 complete cytogenetic response 60 prospectively defined 60 Severity Index PASI 60 mIU mL 60 sunitinib 60 Viread Emtriva Sustiva 60 Cimzia ® 60 ARCALYST ® 60 tamoxifen Nolvadex ® 60 romiplostim 60 GOUT 60 aminotransferases 60 Secondary endpoints included 60 SSRI SNRI 60 somatostatin analog 60 peginterferon 60 ancrod 60 docetaxel Taxotere ® 60 NovoLog ® Mix 60 CDAI 60 stable angina pectoris 60 remission induction 60 autoantibody positive 60 divalproex 60 CLL SLL 60 pegylated interferon alfa 60 pulmonary exacerbations 60 REMINYL ® 60 inhaled corticosteroid ICS 60 % Confidence Interval 60 intramuscularly 60 rotigotine 60 baseline LDH 60 ddI 60 composite endpoint 60 NEXIUM 60 goserelin 60 urate lowering 60 angiotensin converting enzyme inhibitors 60 SPRYCEL 60 Viread Emtriva 60 anthracycline taxane 60 INC# 60 mg/# hours 60 leukemia AML 60 CYPHER Stent 60 Pred Forte 60 placebo controlled clinical 60 FOLFIRI alone 60 RGT arm 60 idraparinux 60 sorafenib Nexavar ® 60 Response Evaluation Criteria 60 dosing regimens 60 valacyclovir 60 COPAXONE R 60 VIRAMUNE 60 recurrent glioblastoma multiforme 60 octreotide acetate 60 intravitreal injections 60 INTELENCE 60 nonvertebral fractures 60 Natalizumab 60 refractory chronic lymphocytic 60 pamidronate 60 liver histology 60 tacrolimus ointment 60 metastatic HRPC 60 FIRMAGON 60 dose escalation 60 subcutaneous injections 60 acromegalic patients 60 ritonavir boosted lopinavir 60 creatinine clearance 60 FDA defined valvulopathy 60 ALT elevations 60 corticosteroid dose 60 remission CR 60 metastatic renal cell carcinoma 60 Pegylated Interferon 60 paricalcitol 60 safety tolerability pharmacokinetics 60 maximal doses 60 metastatic CRC 60 relapsed myeloma 60 non inferiority 60 lopinavir 60 titrated glipizide 60 mEq L 60 analgesic efficacy 60 lipid lowering agents 60 trastuzumab Herceptin R 60 primary efficacy endpoint 60 recurrent VTE 60 tenofovir FTC 60 intraocular inflammation 60 aripiprazole 60 Platinol ® 60 otamixaban 60 Peginterferon alfa 2b 60 RESIST studies 60 randomized placebo controlled 60 #mg ritonavir 60 glycated hemoglobin levels 60 #mg/#mg 60 dimeglumine 60 dextromethorphan quinidine 60 beta 1a 60 pimecrolimus cream 60 CDAI score 60 % CI #.#-#.# [003] 60 metformin monotherapy 60 atorvastatin #mg 60 ispinesib administered 60 blind randomized 60 CCX# B 60 dosing interval 60 iodixanol 60 rimonabant #mg 60 ACEIs 60 serum HCV RNA 60 undetectable viral load 60 postintervention 60 serum phosphorus 60 mg hydrochlorothiazide 60 briakinumab 60 TREDAPTIVE 60 ACE inhibitor ramipril 60 viral kinetics 60 multicenter randomized 60 controlled multicenter 60 budesonide formoterol 60 renal insufficiency 60 palonosetron 60 Pegylated interferon 60 IU mL 60 low dose dexamethasone 60 #/#mg 60 Darunavir 60 myopathy rhabdomyolysis 60 blind randomized placebo 60 cell lymphoma CTCL 60 cytogenetic responses 60 demonstrated clinically meaningful 60 lanthanum carbonate 60 metastatic GIST 60 hours postdose 60 complete remissions 60 budesonide 60 progression TTP 60 SEROQUEL 60 stavudine d4T 60 achieved CCyR 60 Antitumor Activity 60 AGILECT ® 60 detemir 60 MAGE A3 ASCI 60 prednisone prednisolone plus 60 pegIFN 60 Pharmacokinetic 60 salmeterol inhalation powder 60 1mg 2mg 60 abciximab 60 sulphonylurea 60 emtricitabine tenofovir 60 docetaxel Taxotere R 60 Non Responders 60 alvimopan 60 lopinavir ritonavir Kaletra 60 pegylated interferon peg IFN 60 receiving PEGINTRON 60 antihypertensive medications 60 aprepitant 60 Crestor rosuvastatin 60 RAPAFLO R 60 pyrexia 60 REYATAZ ® 60 virologically suppressed 60 hematological parameters 60 Randomized Phase 60 lenalidomide Revlimid R 60 tolterodine 60 HBeAg negative 60 nilotinib 60 Hormone Refractory Prostate Cancer 60 discontinuations 60 Laquinimod 60 Indacaterol 60 ROZEREM TM 60 mg subcutaneous 60 linaclotide treated 60 null responder HCV 60 HbA 1c levels 60 Copegus ® 60 placebo controlled randomized 60 μg mL 60 ACR Pedi 60 ng dl 60 receptor tyrosine kinase inhibitor 60 ribavirin USP 60 COZAAR 60 GAMMAGARD 60 NOXAFIL Oral Suspension

Back to home page